# Shengfang Jin

> Shengfang Jin is a co-founder and the President and CEO of Ensem Therapeutics, a Waltham, Massachusetts biotech developing small-molecule cancer drugs by targeting protein pockets that only exist while the protein is in motion. Under Jin, Ensem built its Kinetic Ensemble platform, took its first CDK2 inhibitor into the clinic, and its ETX-636 breast cancer program earned FDA Fast Track designation. She trained at Tufts and Harvard, spent years at Agios helping deliver first-in-class cancer metabolism drugs, and then ran discovery biology at Editas before starting Ensem.

- **Role:** President and CEO, Ensem Therapeutics
- **Organizations:** Ensem Therapeutics, Editas Medicine (former), Agios Pharmaceuticals (former), CBC Group (former)
- **Education:** Ph.D., Molecular Biology and Microbiology, Tufts University School of Medicine, Postdoctoral training in Oncology and Tumor Immunology (NIH Fellow), Harvard Medical School
- **Known for:** Co-founder of Ensem Therapeutics, Built the Kinetic Ensemble drug-discovery platform, Closed $67M Series A (2023)

## Career timeline

- **pre-2016** — Senior Director of Biology at Agios Pharmaceuticals; contributed to IDHIFA, TIBSOVO, and PYRUKYND
- **prior** — Vice President of Discovery Biology at Editas Medicine
- **prior** — Operating Partner, CBC Group
- **2021** — Co-founded Ensem Therapeutics; served as President and Chief Scientific Officer
- **2023-06** — Promoted to President and CEO of Ensem Therapeutics
- **2023-10** — Closed $67M Series A financing
- **2024-06** — Ensem's CDK2 inhibitor ETX-197 enters clinical trials in solid tumors
- **2025-01** — Presented at 43rd Annual J.P. Morgan Healthcare Conference
- **2025** — ETX-636 granted FDA Fast Track designation for advanced breast cancer

## Achievements

- Co-founder of Ensem Therapeutics
- Built the Kinetic Ensemble drug-discovery platform
- Closed $67M Series A (2023)
- Advanced first clinical candidate ETX-197 (CDK2 inhibitor) into human trials
- Secured FDA Fast Track designation for ETX-636 in advanced breast cancer
- Co-author/co-inventor on 80+ peer-reviewed publications and patents
- Biology leadership contributed to FDA approvals of IDHIFA, TIBSOVO, and PYRUKYND at Agios

## Latest updates

- **2025-01** — Ensem presented at the 43rd Annual J.P. Morgan Healthcare Conference.
- **2025** — ETX-636 received FDA Fast Track designation for advanced breast cancer.
- **2024-06** — Ensem's CDK2 inhibitor entered clinical trials for solid tumors.

## Links

- Website: https://ensemtx.com
- LinkedIn: https://www.linkedin.com/in/shengfang-jin-713360/

---

Profile page: https://yespress.io/shengfang-jin
Published by YesPress — https://yespress.io
Last updated: 2026-07-08